# SECURITIES AND FUTURES ACT (CAP. 289) SECURITIES AND FUTURES (DISCLOSURE OF INTERESTS) REGULATIONS 2012

## NOTIFICATION FORM FOR SUBSTANTIAL SHAREHOLDER(S)/UNITHOLDER(S) IN RESPECT OF INTERESTS IN

FORM

3
(Electronic Format)

#### **Explanatory Notes**

- 1. Please read the explanatory notes carefully before completing the notification form.
- 2. This form is for a Substantial Shareholder(s)/Unitholder(s) to give notice under section 135, 136, 137, 137J (as applicable to sections 135, 136 and 137) or 137U (as applicable to sections 135, 136 and 137) of the Securities and Futures Act (the "SFA").
- 3. This electronic Form 3 and a separate Form C, containing the particulars and contact details of the Substantial Shareholder(s)/Unitholder(s), must be completed by the Substantial Shareholder(s)/Unitholder(s) or a person duly authorised by the Substantial Shareholder(s)/Unitholder(s) to do so. The person so authorised should maintain records of information furnished to him by the Substantial Shareholder(s)/Unitholder(s).
- 4. This form and Form C, are to be completed electronically and sent to the Listed Issuer via an electronic medium such as an e-mail attachment. The Listed Issuer will attach both forms to the prescribed SGXNet announcement template for dissemination as required under section 137G(1), 137R(1) or 137ZC(1) of the SFA, as the case may be. While Form C will be attached to the announcement template, it will not be disseminated to the public and is made available only to the Monetary Authority of Singapore (the "Authority").
- 5. Where a transaction results in similar notifiable obligations on the part of more than one Substantial Shareholder/Unitholder, all of these Substantial Shareholders/Unitholders may give notice using the same notification form.
- 6. A single form may be used by a Substantial Shareholder/Unitholder for more than one transaction resulting in notifiable obligations which occur within the same notifiable period (i.e. within two business days of becoming aware of the earliest transaction). There must be no netting-off of two or more notifiable transactions even if they occur within the same day.
- 7. All applicable parts of the notification form must be completed. If there is insufficient space for your answers, please include attachment(s) by clicking the paper clip icon on the bottom left-hand corner or in item 11 of Part II or item 10 of Part III. The total file size for all attachment(s) should not exceed 1MB.
- 8. Except for item 5 of Part II and item 1 of Part IV, please select only one option from the relevant check boxes.
- 9. Please note that submission of any false or misleading information is an offence under Part VII of the SFA.
- 10. In this form, the term "Listed Issuer" refers to -
  - (a) a company incorporated in Singapore any or all of the shares in which are listed for quotation on the official list of a securities exchange;
  - (b) a corporation (not being a company incorporated in Singapore, or a collective investment scheme constituted as a corporation) any or all of the shares in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing;

- (c) a registered business trust (as defined in the Business Trusts Act (Cap. 31A)) any or all of the units in which are listed for quotation on the official list of a securities exchange;
- (d) a recognised business trust any or all of the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing; or
- (e) a collective investment scheme that is a trust, that invests primarily in real estate and real estaterelated assets specified by the Authority in the Code on Collective Investment Schemes, and any or all the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing ("Real Estate Investment Trust").
- 11. For further instructions and guidance on how to complete this notification form, please refer to section 7 of the User Guide on Electronic Notification Forms which can be accessed at the Authority's Internet website at <a href="http://www.mas.gov.sg">http://www.mas.gov.sg</a> (under "Regulations and Financial Stability", "Regulations, Guidance and Licensing", "Securities, Futures and Fund Management", "Forms", "Disclosure of Interests").

#### Part I - General

	r art i - General
1.	Name of Listed Issuer:
	ASIAMEDIC LIMITED
2.	Type of Listed Issuer:  ✓ Company/Corporation  ☐ Registered/Recognised Business Trust
3.	Real Estate Investment Trust  Is more than one Substantial Shareholder/Unitholder giving notice in this form?
	<ul> <li>No (Please proceed to complete Part II)</li> <li>✓ Yes (Please proceed to complete Parts III &amp; IV)</li> </ul>
1.	Date of notification to Listed Issuer:
	14-Jan-2020

#### Part III - Substantial Shareholder(s)/Unitholder(s) Details

[To be used for multiple Substantial Shareholders/Unitholders to give notice]

Substantial Shareholder/Unitholder 🗛
--------------------------------------



<u>Sub</u> 1.	Name of Substantial Shareholder/Unitholder:
	LUYE MEDICAL GROUP PTE. LTD.
2.	Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No
3.	Notification in respect of:
	Becoming a Substantial Shareholder/Unitholder
	✓ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
	Ceasing to be a Substantial Shareholder/Unitholder
4.	Date of acquisition of or change in interest:
	14-Jan-2020
5.	Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (if different from item 4 above, please specify the date):
	14-Jan-2020
6.	Explanation (if the date of becoming aware is different from the date of acquisition of, or the change in, interest):

7. Quantum of total voting shares/units (including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	95,431,396	0	95,431,396
As a percentage of total no. of voting shares/t(i):	24.44	0	24.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
Immediately after the transaction  No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	Direct Interest 512,098,062	Deemed Interest  0	<i>Total</i> 512,098,062

9.	Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]
	Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.
	Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the Securities & Futures Act ("SFA").
	Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.
10.	Attachments (if any): 🕤
	(The total file size for all attachment(s) should not exceed 1MB.)
11.	If this is a <b>replacement</b> of an earlier notification, please provide:
	(a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (the "Initial Announcement"):
	(b) Date of the Initial Announcement:

	(c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
12.	Remarks ( <i>if any</i> ):
	The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).  The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).
Sub	estantial Shareholder/Unitholder B
1.	Name of Substantial Shareholder/Unitholder:
	LUYE MEDICAL INVESTMENT PTE. LTD.
2.	Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No
3.	Notification in respect of:
	Becoming a Substantial Shareholder/Unitholder
	✓ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
	Ceasing to be a Substantial Shareholder/Unitholder
4.	Date of acquisition of or change in interest:
	14-Jan-2020
5.	Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (if different from item 4 above, please specify the date):
	14-Jan-2020
6.	Explanation (if the date of becoming aware is different from the date of acquisition of, or the change in, interest):
7.	Quantum of total voting shares/units (including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}) held by Substantial Shareholder/Linitholder before and after the transaction:

rights/options/warrants/convertible debentures:

As a percentage of total no. of voting shares/t	0	24.44	24.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	0	512,098,062	512,098,062
As a percentage of total no. of voting shares/t	0	45.74	45.74

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

	Attac	chments ( <i>if any</i> ): 🕤
	Ø	(The total file size for all attachment(s) should not exceed 1MB.)
11.	If this	s is a <b>replacement</b> of an earlier notification, please provide:
	(a)	SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (the "Initial Announcement"):
	(b)	Date of the Initial Announcement:
	(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
12.	Rem	arks ( <i>if any</i> ):
		ercentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid
	up sna	ares in the capital of AsiaMedic Limited (excluding treasury shares).
		ercentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up in the capital of AsiaMedic Limited (excluding treasury shares).
	Si idi oc	The deplication / Islamical Chordaining treasury strategy.
Sub	etantis	al Shareholder/Unitholder C
<u>Jub.</u>	Staritie	al Shareholder/Unitholder C
1.	Nam	e of Substantial Shareholder/Unitholder:
	LUYE	LIFE SCIENCES GROUP LTD
2.		
3.	Notif	ication in respect of:
		ecoming a Substantial Shareholder/Unitholder
	✓ C	hange in the percentage level of interest while still remaining a Substantial Shareholder/Unitholde
	□ C	easing to be a Substantial Shareholder/Unitholder
4.	Date	of acquisition of or change in interest:
4.		of acquisition of or change in interest:
	14-Jai	
4. 5.	14-Jar Date chan	on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the

				n}) held by Substan
	Shareholder/Unitholder before and	d after the transac	tion:  Deemed Interest	Total
No	Immediately before the transaction  of voting shares/units held and/or	0	95,431,396	95,431,396
un	derlying the nts/options/warrants/convertible debentures:			
	a percentage of total no. of voting ares/ເ	0	24.44	24.44
	Immediately after the transaction	Direct Interest	Deemed Interest	Total
un	of voting shares/units held and/or derlying the rights/options/warrants/overtible debentures:	0	512,098,062	512,098,062
	a percentage of total no. of voting ares/t	0	45.74	45.74
8.	Circumstances giving rise to deem [You may attach a chart in item 10 to			er/Unitholder's deeme
8.		illustrate how the So of the issued and pa ment Pte. Ltd. is deer e of Section 4 of the S	ubstantial Shareholde nid-up share capital of I med to have an interes FA. Accordingly, Luye	Luye Medical t in the Shares held Life Sciences Group
<ol> <li>8.</li> <li>9.</li> </ol>	[You may attach a chart in item 10 to interest arises]  Luye Life Sciences Group Ltd holds 100% Investment Pte. Ltd. Luye Medical Invest by Luye Medical Group Pte. Ltd. by virtue Ltd is deemed to have an interest in the	illustrate how the So of the issued and pa ment Pte. Ltd. is deer e of Section 4 of the S Shares held by Luye N	ubstantial Shareholde nid-up share capital of I med to have an interes FA. Accordingly, Luye Medical Group Pte. Ltd	Luye Medical t in the Shares held Life Sciences Group by virtue of Section 4
	[You may attach a chart in item 10 to interest arises]  Luye Life Sciences Group Ltd holds 100% Investment Pte. Ltd. Luye Medical Invest by Luye Medical Group Pte. Ltd. by virtue Ltd is deemed to have an interest in the of the SFA.  Relationship between the Substan [You may attach a chart in item 10 to	illustrate how the So of the issued and pa ment Pte. Ltd. is deer e of Section 4 of the S Shares held by Luye N	ubstantial Shareholde nid-up share capital of I med to have an interes FA. Accordingly, Luye Medical Group Pte. Ltd	Luye Medical t in the Shares held Life Sciences Group by virtue of Section 4
	[You may attach a chart in item 10 to interest arises]  Luye Life Sciences Group Ltd holds 100% Investment Pte. Ltd. Luye Medical Invest by Luye Medical Group Pte. Ltd. by virtue Ltd is deemed to have an interest in the of the SFA.  Relationship between the Substan [You may attach a chart in item 10 to	illustrate how the So of the issued and pa ment Pte. Ltd. is deer e of Section 4 of the S Shares held by Luye N	ubstantial Shareholde nid-up share capital of I med to have an interes FA. Accordingly, Luye Medical Group Pte. Ltd	Luye Medical t in the Shares held Life Sciences Group by virtue of Section 4
	[You may attach a chart in item 10 to interest arises]  Luye Life Sciences Group Ltd holds 100% Investment Pte. Ltd. Luye Medical Invest by Luye Medical Group Pte. Ltd. by virtue Ltd is deemed to have an interest in the of the SFA.  Relationship between the Substan [You may attach a chart in item 10 to	illustrate how the So of the issued and pa ment Pte. Ltd. is deer e of Section 4 of the S Shares held by Luye N	ubstantial Shareholde nid-up share capital of I med to have an interes FA. Accordingly, Luye Medical Group Pte. Ltd	Luye Medical t in the Shares held Life Sciences Group by virtue of Section 4

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. Ltd. Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

10. Attachments (if any): 🕦



(The total file size for all attachment(s) should not exceed 1MB.)

<ol> <li>If this is a replacement of an earlier notification, please present</li> </ol>	JI OVIGE.
---	-----------

a)	SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (the "Initial Announcement"):
b)	Date of the Initial Announcement:
c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:

12. Remarks (if any):

The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

Name of Substantial Shareholder/Unitholder:
NELUMBO INVESTMENTS LIMITED
Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?  Yes
✓ No
Notification in respect of:  Becoming a Substantial Shareholder/Unitholder
✓ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholde
Ceasing to be a Substantial Shareholder/Unitholder
Date of acquisition of or change in interest:
14-Jan-2020
Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (if different from item 4 above, please specify the date):
14-Jan-2020
Explanation (if the date of becoming aware is different from the date of acquisition of, or the change in, interest):

7. Quantum of total voting shares/units (including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	95,431,396	95,431,396
As a percentage of total no. of voting shares/():	0	24.44	24.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
Immediately after the transaction  No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	Direct Interest	Deemed Interest 512,098,062	Total 512,098,062

	Circumstances giving rise to deemed interests (if the interest is such): [You may attach a chart in item 10 to illustrate how the Substantial Shareholder/Unitholder's deemed interest arises]
	Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd. by Virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by Virtue of Section 4 of the SFA.
	Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]
	Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.
	Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.
	Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.
١.	Attachments (if any): 🕥
	(The total file size for all attachment(s) should not exceed 1MB.)
	If this is a <b>replacement</b> of an earlier notification, please provide:

11. If this is a **replacement** of an earlier notification, please provide:

(a)	SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (the "Initial Announcement"):
(h)	Date of the Initial Announcement:

(b) Date of the Initial Announcement:

	(c) 15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
12.	Remarks ( <i>if any</i> ):
	The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).  The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).
Sub	ostantial Shareholder/Unitholder E
1.	Name of Substantial Shareholder/Unitholder:
	GINKGO (PTC) LIMITED
2.	Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No
3.	Notification in respect of:
	Becoming a Substantial Shareholder/Unitholder
	✓ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
	Ceasing to be a Substantial Shareholder/Unitholder
4.	Date of acquisition of or change in interest:
	14-Jan-2020
5.	Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (if different from item 4 above, please specify the date):
	14-Jan-2020
6.	Explanation (if the date of becoming aware is different from the date of acquisition of, or the change in, interest):
7.	Quantum of total voting shares/units (including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}) held by Substantial Shareholder/Linitholder before and after the transaction:

Shareholder/Unitholder before and after the transaction:

Immediately before the transaction

Direct Interest

Deemed Interest

Total

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:		95,431,396	95,431,396

As a percentage of total no. of voting shares/til:	0	24.44	24.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	0	512,098,062	512,098,062
As a percentage of total no. of voting shares/t	0	45.74	45.74

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

on SGXNet (the "Initial Announcement"):  (b) Date of the Initial Announcement:  (c) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  (c) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  (d) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  (e) 15-digit transaction in the Initial Announcement:  (f) 12-digit transaction in the Form which was attached in the Initial Announcement:  (g) 15-digit transaction in the Form which and up shares in the Capital of AsiaMedic Limited (excluding treasury shares).  (g) 17-digit Transaction in Calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  (g) 18-digit Transaction in Calculated based on 1,119,522,270 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the Capital Asia Medic Limited (excluding treasury shares).  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the Capital Announcement:  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the Capital Announcement:  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the Capital Announcement:  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the Capital Announcement:  (g) 19-digit Transaction in Calculated based on 390,488,125 issued and up shares in the Capital Announcement:  (g) 19-digit Transa		Attac	chments ( <i>if any</i> ): 🕥
(a) SGXNet announcement reference of the first notification which was announce on SGXNet (the "Initial Announcement"):  (b) Date of the Initial Announcement:  (c) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  Substantial Shareholder/Unitholder F  1. Name of Substantial Shareholder/Unitholder:  SHOREA LBG  2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No  3. Notification in respect of:  Becoming a Substantial Shareholder/Unitholder  Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder  Ceasing to be a Substantial Shareholder/Unitholder  4. Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder/Date of the acquisition of,		Ø	(The total file size for all attachment(s) should not exceed 1MB.)
on SGXNet (the "Initial Announcement"):  (b) Date of the Initial Announcement:  (c) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  (c) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  (d) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  (e) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:  (f) 15-digit transaction in the Initial Announcement:  (g) 15-digit transaction in the Form which was attached in the Initial Announcement:  (g) 16-digit Transaction in calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  The percentage of shareholder (unithed (excluding treasury shares).  Substantial Shareholder/Unitholder:  (g) 18-digit Transaction in calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  Substantial Shareholder/Unitholder:  (g) 19-digit Transaction in calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  Substantial Shareholder/Unitholder:  (g) 19-digit Transaction in calculated based on 390,488,125 issued and up shares.  (h) 19-digit Transaction in the Form which Substantial Shareholder/Unitholder for the reasonable part of the relevant transaction in the Form which Substantial Shareholder/Unitholder became aware of the acquisition of, of, or calculated based on 390,488,125 issued and up shareholder/Unitholder became aware of the acquisition of, or calculated based on 390,488,125 issued and up shareholder/Unitholder became aware of the acquisition of, or calculated based on 1,119,522,270 issued and up shareholder/Unitholder for acquisition in the Form which shareholder/Unitholder for acquisition in the Form	11.	If this	s is a <b>replacement</b> of an earlier notification, please provide:
(c) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:		(a)	SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (the "Initial Announcement"):
(c) 15-digit transaction reference number of the relevant transaction in the Form which was attached in the Initial Announcement:		(b)	Date of the Initial Appendement:
which was attached in the Initial Announcement:		(D)	Date of the initial Africoncement.
The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and shares in the capital of AsiaMedic Limited (excluding treasury shares).  Substantial Shareholder/Unitholder F  1. Name of Substantial Shareholder/Unitholder:  SHOREA LBG  2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No  Notification in respect of:  Becoming a Substantial Shareholder/Unitholder  Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder  Ceasing to be a Substantial Shareholder/Unitholder  Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,		(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and up shares in the capital of AsiaMedic Limited (excluding treasury shares).  The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and shares in the capital of AsiaMedic Limited (excluding treasury shares).  Substantial Shareholder/Unitholder F  1. Name of Substantial Shareholder/Unitholder:  SHOREA LBG  2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No  Notification in respect of:  Becoming a Substantial Shareholder/Unitholder  Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder  Ceasing to be a Substantial Shareholder/Unitholder  Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,			
up shares in the capital of AsiaMedic Limited (excluding treasury shares).  The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and phases in the capital of AsiaMedic Limited (excluding treasury shares).  Substantial Shareholder/Unitholder F  1. Name of Substantial Shareholder/Unitholder:  SHOREA LBG  2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No  3. Notification in respect of:  Becoming a Substantial Shareholder/Unitholder  Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder  Ceasing to be a Substantial Shareholder/Unitholder  4. Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,	12.	Rem	arks (if any):
Substantial Shareholder/Unitholder F  1. Name of Substantial Shareholder/Unitholder:  SHOREA LBG  2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No  3. Notification in respect of:  Becoming a Substantial Shareholder/Unitholder  Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder  Ceasing to be a Substantial Shareholder/Unitholder  4. Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,			
Substantial Shareholder/Unitholder F  1. Name of Substantial Shareholder/Unitholder:  SHOREA LBG  2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No  3. Notification in respect of:  Becoming a Substantial Shareholder/Unitholder  Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder  Ceasing to be a Substantial Shareholder/Unitholder  4. Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,			ercentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up
<ol> <li>Name of Substantial Shareholder/Unitholder:         SHOREA LBG     </li> <li>Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?         Yes         No     </li> <li>Notification in respect of:         Becoming a Substantial Shareholder/Unitholder         Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder     </li> <li>Date of acquisition of or change in interest:         14-Jan-2020     </li> <li>Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,</li> </ol>		Silaros	The suprice of Asianical Elimica (excluding trousary shares).
SHOREA LBG  2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No  Notification in respect of:  Becoming a Substantial Shareholder/Unitholder  Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder  Ceasing to be a Substantial Shareholder/Unitholder  4. Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,	<u>Sub</u>	stantia	al Shareholder/Unitholder F
2. Is Substantial Shareholder/Unitholder a fund manager or a person whose interest securities of the Listed Issuer are held solely through fund manager(s)?  ☐ Yes ☐ No  3. Notification in respect of: ☐ Becoming a Substantial Shareholder/Unitholder ☐ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder ☐ Ceasing to be a Substantial Shareholder/Unitholder  4. Date of acquisition of or change in interest: ☐ 14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,	1.	Nam	e of Substantial Shareholder/Unitholder:
securities of the Listed Issuer are held solely through fund manager(s)?  Yes No  Notification in respect of: Becoming a Substantial Shareholder/Unitholder Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder Ceasing to be a Substantial Shareholder/Unitholder  Date of acquisition of or change in interest:  14-Jan-2020  Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,		SHOR	EA LBG
<ul> <li>□ Becoming a Substantial Shareholder/Unitholder</li> <li>☑ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder</li> <li>□ Ceasing to be a Substantial Shareholder/Unitholder</li> <li>4. Date of acquisition of or change in interest:</li> <li>□ 14-Jan-2020</li> <li>5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,</li> </ul>	2.	secu	es
<ul> <li>✓ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder</li> <li>Ceasing to be a Substantial Shareholder/Unitholder</li> <li>Date of acquisition of or change in interest:         <ul> <li>14-Jan-2020</li> </ul> </li> <li>Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,</li> </ul>	3.		·
Ceasing to be a Substantial Shareholder/Unitholder  4. Date of acquisition of or change in interest:  14-Jan-2020  5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,			
14-Jan-2020  Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,			
14-Jan-2020  Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,	4	Date	of acquisition of or change in interest:
5. Date on which Substantial Shareholder/Unitholder became aware of the acquisition of,			
14-Jan-2020	5.		n-2020 e on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the
	5.	chan	n-2020  on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the age in, interest (if different from item 4 above, please specify the date):

	Shareholder/Unitholder before and			1
	Immediately before the transaction	Direct Interest	Deemed Interest	Total
un	. of voting shares/units held and/or derlying the nts/options/warrants/convertible debentures:	0	95,431,396	95,431,396
	a percentage of total no. of voting ares/t	0	24.44	24.44
	Immediately after the transaction	Direct Interest	Deemed Interest	Total
un	. of voting shares/units held and/or derlying the rights/options/warrants/ nvertible debentures :	0	512,098,062	512,098,062
	a percentage of total no. of voting ares/t	0	45.74	45.74
	interest arises] Shorea LBG holds 100% of the issued and wholly-owned by Mr Liu Dianbo. Ginkgo Luye Medical Group Pte. Ltd. by virtue of Dianbo are deemed to be indirectly inter	(PTC) Limited is deel Section 4 of the SFA	med to have an interes . Accordingly, each of S	t in the Shares held by Shorea LBG and Mr Liu
9.	Relationship between the Substant [You may attach a chart in item 10 to s Shareholders/Unitholders]			

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. Ltd. Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

10. Attachments (if any): 🕦



(The total file size for all attachment(s) should not exceed 1MB.)

11.	If this is a	replacement o	of an earlier	notification.	please	provide:

(a)	SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet ( <i>the "Initial Announcement"</i> ):
(b)	Date of the Initial Announcement:
(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:

12. Remarks (if any):

The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

	e of Substantial Shareholder/Unitholder:
THE AS	SOKA TRUST
Notifi	cation in respect of:
Ве	ecoming a Substantial Shareholder/Unitholder
✓ Cł	nange in the percentage level of interest while still remaining a Substantial Shareholder/Unithold
_ Ce	easing to be a Substantial Shareholder/Unitholder
Date	of acquisition of or change in interest:
14-Jar	1-2020
	on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the ge in, interest (if different from item 4 above, please specify the date):
14-Jar	-2020
•	nation (if the date of becoming aware is different from the date of acquisition of, or the ge in, interest):

7. Quantum of total voting shares/units (including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	95,431,396	95,431,396
As a percentage of total no. of voting shares/(	0	24.44	24.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
Immediately after the transaction  No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	Direct Interest	Deemed Interest 512,098,062	Total 512,098,062

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

10.	Attachments	(if any):	
-----	-------------	-----------	--



(The total file size for all attachment(s) should not exceed 1MB.)

- 11. If this is a **replacement** of an earlier notification, please provide:
  - (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (*the "Initial Announcement"*):

	(b)	Date of the Initial Announcement:
	(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
40	Б.	
12.		arks (if any):
		ercentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid ares in the capital of AsiaMedic Limited (excluding treasury shares).
	The pe	ercentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up
		in the capital of AsiaMedic Limited (excluding treasury shares).
Sub:	<u>stantia</u>	ul Shareholder/Unitholder H
1.	Nam	e of Substantial Shareholder/Unitholder:
	LIU DI	ANBO
2.		
3.	Notifi	ication in respect of:
	□ Ве	ecoming a Substantial Shareholder/Unitholder
	✓ C	hange in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
	C	easing to be a Substantial Shareholder/Unitholder
4.	Date	of acquisition of or change in interest:
	14-Jar	n-2020
5.		on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the ge in, interest (if different from item 4 above, please specify the date):
	14-Jar	n-2020
6.	•	anation (if the date of becoming aware is different from the date of acquisition of, or the ge in, interest):
7.	rights	ntum of total voting shares/units (including voting shares/units underlying s/options/warrants/convertible debentures {conversion price known}) held by Substantial eholder/Unitholder before and after the transaction:
	lmmed	liately before the transaction

No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	95,431,396	95,431,396
As a percentage of total no. of voting shares/(	0	28.44	28.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
Immediately after the transaction	Direct interest	Deemed interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	0	512,098,062	512,098,062

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

10. Attachments (if any):



(The total file size for all attachment(s) should not exceed 1MB.)

11	If this is a	replacement	of an	earlier notification	nlease	nrovide:
1 1.	11 11113 13 4	I CDIACCIIICIIL	OI all	Carner Hountauter	. Dicasc	DIOVIGE.

(a)	on SGXNet (the "Initial Announcement"):
(b)	Date of the Initial Announcement:
(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:

12. Remarks (if any):

The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

Name of Substantial Shareholder/Unitholder:
WANG CUILIAN
Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?  Yes No
Notification in respect of:
Becoming a Substantial Shareholder/Unitholder
✓ Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
Ceasing to be a Substantial Shareholder/Unitholder
Date of acquisition of or change in interest:
14-Jan-2020
Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (i) (if different from item 4 above, please specify the date):
14-Jan-2020
Explanation (if the date of becoming aware is different from the date of acquisition of, or the change in, interest):
change in, interest):

7. Quantum of total voting shares/units (including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	95,431,396	95,431,396
As a percentage of total no. of voting shares/():	0	24.44	24.44
	1		
Immediately after the transaction	Direct Interest	Deemed Interest	Total
Immediately after the transaction  No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	Direct Interest	Deemed Interest 512,098,062	Total 512,098,062

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

10.	Attachments	(if any):	
-----	-------------	-----------	--



(The total file size for all attachment(s) should not exceed 1MB.)

- 11. If this is a **replacement** of an earlier notification, please provide:
  - (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (*the "Initial Announcement"*):

	(b)	Date of the Initial Announcement:
	(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
12.	Rem	arks ( <i>if any</i> ):
		ercentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid ares in the capital of AsiaMedic Limited (excluding treasury shares).
		ercentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up in the capital of AsiaMedic Limited (excluding treasury shares).
Sub	stantia	I Shareholder/Unitholder J
1.	Nam	e of Substantial Shareholder/Unitholder:
	AONA	LIU
2.		
3.	Notifi	cation in respect of:
	□ Ве	ecoming a Substantial Shareholder/Unitholder
	✓ C	hange in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
	C	easing to be a Substantial Shareholder/Unitholder
4.	Date	of acquisition of or change in interest:
	14-Jar	n-2020
5.		on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the ge in, interest (if different from item 4 above, please specify the date):
	14-Jar	n-2020
6.	•	anation (if the date of becoming aware is different from the date of acquisition of, or the ge in, interest):
	_	
7.	rights	ntum of total voting shares/units (including voting shares/units underlying s/options/warrants/convertible debentures (conversion price known)) held by Substantial eholder/Unitholder before and after the transaction:
	Immed	iately before the transaction

No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	95,431,396	95,431,396
As a percentage of total no. of voting shares/(	0	24.44	24.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
ininicalatory after the transaction	Direct interest	Deemed interest	rotar
No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	0	512,098,062	512,098,062

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

10. Attachments (if any):



(The total file size for all attachment(s) should not exceed 1MB.)

11	If this is a	replacement	of an	earlier notification	nlease	provide:
1 1.	11 11113 13 4	I CDIACCIIICIIL	oi aii		. Dicasc	provide.

(a)	on SGXNet (the "Initial Announcement"):
(b)	Date of the Initial Announcement:
(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:

12. Remarks (if any):

The percentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

The percentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up shares in the capital of AsiaMedic Limited (excluding treasury shares).

<u> </u>	stantial Shareholder/Unitholder K  Name of Substantial Shareholder/Unitholder:
	ALINA W LIU
	Is Substantial Shareholder/Unitholder a fund manager or a person whose interest in the securities of the Listed Issuer are held solely through fund manager(s)?  Yes  No
	Notification in respect of:
	Becoming a Substantial Shareholder/Unitholder
	Change in the percentage level of interest while still remaining a Substantial Shareholder/Unitholder
	Ceasing to be a Substantial Shareholder/Unitholder
	Date of acquisition of or change in interest:
	14-Jan-2020
	Date on which Substantial Shareholder/Unitholder became aware of the acquisition of, or the change in, interest (if different from item 4 above, please specify the date):
	14-Jan-2020
	Explanation (if the date of becoming aware is different from the date of acquisition of, or the change in, interest):

7. Quantum of total voting shares/units (including voting shares/units underlying rights/options/warrants/convertible debentures {conversion price known}) held by Substantial Shareholder/Unitholder before and after the transaction:

Immediately before the transaction	Direct Interest	Deemed Interest	Total
No. of voting shares/units held and/or underlying the rights/options/warrants/convertible debentures:	0	95,431,396	95,431,396
As a percentage of total no. of voting shares/(	0	24.44	24.44
Immediately after the transaction	Direct Interest	Deemed Interest	Total
Immediately after the transaction  No. of voting shares/units held and/or underlying the rights/options/warrants/ convertible debentures :	Direct Interest	Deemed Interest 512,098,062	Total 512,098,062

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

9. Relationship between the Substantial Shareholders/Unitholders giving notice in this form: [You may attach a chart in item 10 to show the relationship between the Substantial Shareholders/Unitholders]

Luye Medical Group Pte. Ltd. holds its shares in the AsiaMedic Limited ("Shares") directly.

Luye Medical Investment Pte. Ltd. holds 100% of the issued and paid-up share capital of Luye Medical Group Pte. Ltd. and is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Luye Life Sciences Group Ltd holds 100% of the issued and paid-up share capital of Luye Medical Investment Pte. Ltd. is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Nelumbo Investments Limited holds 70% of the issued and paid up share capital of Luye Life Sciences Group Ltd. Luye Life Sciences Group Ltd is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are held by Ginkgo (PTC) Limited as trustee of The Asoka Trust. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

The shares representing 100% of the issued and paid up share capital of Nelumbo Investments Limited are the trust property of The Asoka Trust. The settlor of The Asoka Trust is Mr Liu Dianbo. The beneficiaries of The Asoka Trust are Mr Liu Dianbo, his spouse Mdm Wang Cuilian, and his daughters Ms Aona Liu and Ms Alina W Liu. Nelumbo Investments Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, The Asoka Trust and the beneficiaries of The Asoka Trust are deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA.

Shorea LBG holds 100% of the issued and paid up share capital of Ginkgo (PTC) Limited and is in turn wholly-owned by Mr Liu Dianbo. Ginkgo (PTC) Limited is deemed to have an interest in the Shares held by Luye Medical Group Pte. Ltd. by virtue of Section 4 of the SFA. Accordingly, each of Shorea LBG and Mr Liu Dianbo are deemed to be indirectly interested in the Shares that Ginkgo (PTC) Limited has an interest in.

10.	Attachments	(if any):	
-----	-------------	-----------	--



(The total file size for all attachment(s) should not exceed 1MB.)

- 11. If this is a **replacement** of an earlier notification, please provide:
  - (a) SGXNet announcement reference of the <u>first</u> notification which was announced on SGXNet (the "Initial Announcement"):

	(b)	Date of the Initial Announcement:
	(c)	15-digit transaction reference number of the relevant transaction in the Form 3 which was attached in the Initial Announcement:
12.	Rem	arks ( <i>if any</i> ):
		ercentage of shareholding prior to the transaction is calculated based on 390,488,125 issued and paid ares in the capital of AsiaMedic Limited (excluding treasury shares).
		ercentage of shareholding after the transaction is calculated based on 1,119,522,270 issued and paid up in the capital of AsiaMedic Limited (excluding treasury shares).

### Part IV - Transaction details

1.	Type of securities which are the subject of the transaction (more than one option may be chosen):
	✓ Voting shares/units
	Rights/Options/Warrants over voting shares/units
	Convertible debentures over voting shares/units (conversion price known)
	Others (please specify):
2.	Number of shares, units, rights, options, warrants and/or principal amount of convertible debentures acquired or disposed of by Substantial Shareholders/Unitholders:
	416,666,666
3.	Amount of consideration paid or received by Substantial Shareholders/Unitholders (excluding brokerage and stamp duties):
	S\$5,000,000
4.	Circumstance giving rise to the interest or change in interest:
	Acquisition of:
	Securities via market transaction
	Securities via off-market transaction (e.g. married deals)
	Securities via physical settlement of derivatives or other securities
	✓ Securities pursuant to rights issue
	Securities via a placement
	Securities following conversion/exercise of rights, options, warrants or other convertibles
	Disposal of:
	Securities via market transaction
	Securities via off-market transaction (e.g. married deals)
	Other circumstances:
	Acceptance of take-over offer for the Listed Issuer
	Corporate action by the Listed Issuer which Substantial Shareholders/Unitholders did not participate in (please specify):
	Others (please specify):

Item 5 is to be completed by an individual submitting this notification form on behalf of the Substantial Shareholders/Unitholders. Particulars of Individual submitting this notification form to the Listed Issuer: 5. (a) Name of Individual: Stanley Woo / Sarah Choong (b) Designation (if applicable): Group Financial Controller / Legal Director (c) Name of entity (if applicable): AsiaMedic Limited / Luye Medical Group Pte. Ltd. Transaction Reference Number (auto-generated): 3 7 8 3 3 3 4 8 1 3 3 6